{"transactions":[{"id":689278,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T18:30:46.000Z","date":"2026-08-11","kind":"other","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":517917,"source":{"system":"sec-edgar","filing":"0001628280-26-056108","document":"wk-form4_1786559443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026056108/wk-form4_1786559443.xml","form_type":"4"}},{"id":689277,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T18:30:46.000Z","date":"2026-08-11","kind":"other","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards."}],"balance_after":40656,"source":{"system":"sec-edgar","filing":"0001628280-26-056108","document":"wk-form4_1786559443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026056108/wk-form4_1786559443.xml","form_type":"4"}},{"id":757225,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:05.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251534","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526251534/ownership.xml","form_type":"4"}},{"id":760234,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:25:00.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038964","document":"wk-form4_1780010697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038964/wk-form4_1780010697.xml","form_type":"4"}},{"id":760233,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:25:00.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":48656,"source":{"system":"sec-edgar","filing":"0001628280-26-038964","document":"wk-form4_1780010697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038964/wk-form4_1780010697.xml","form_type":"4"}},{"id":962125,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T02:00:04.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. (\"APNG II\") on June 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":3823425,"source":{"system":"sec-edgar","filing":"0001193125-25-327254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525327254/ownership.xml","form_type":"4"}},{"id":988808,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T22:00:07.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":246871,"price":20.2536,"value":5000026.4856,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. (\"APNG II\") on June 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":3833425,"source":{"system":"sec-edgar","filing":"0001193125-25-297551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525297551/ownership.xml","form_type":"4"}},{"id":1117959,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T22:39:33.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":true,"shares":14027,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":509917,"source":{"system":"sec-edgar","filing":"0001628280-25-030306","document":"wk-form4_1749508754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030306/wk-form4_1749508754.xml","form_type":"4"}},{"id":1117958,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T22:39:33.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":false,"shares":14027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":40656,"source":{"system":"sec-edgar","filing":"0001628280-25-030306","document":"wk-form4_1749508754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030306/wk-form4_1749508754.xml","form_type":"4"}},{"id":1127706,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:22:07.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028894","document":"wk-form4_1748906520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028894/wk-form4_1748906520.xml","form_type":"4"}},{"id":1127705,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:22:07.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":54683,"source":{"system":"sec-edgar","filing":"0001628280-25-028894","document":"wk-form4_1748906520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028894/wk-form4_1748906520.xml","form_type":"4"}},{"id":1127828,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:08.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025080230/ownership.xml","form_type":"4"}},{"id":1495189,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T16:08:28.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":10.39,"exercise_date":"2025-05-30","expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-026207","document":"wk-form4_1717430899.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026207/wk-form4_1717430899.xml","form_type":"4"}},{"id":1495188,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-03T16:08:28.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":46683,"source":{"system":"sec-edgar","filing":"0001628280-24-026207","document":"wk-form4_1717430899.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026207/wk-form4_1717430899.xml","form_type":"4"}},{"id":1496806,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:30:05.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":18600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":18600,"derivative":{"exercise_price":15.94,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0000950170-24-067361","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024067361/ownership.xml","form_type":"4"}},{"id":1756937,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-20T18:15:56.000Z","date":"2023-10-19","kind":"other","planned":false,"acquired":true,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares transferred for no consideration to APNG 1 upon vesting of an RSU award held by the Reporting Person for the benefit of APNG 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":495890,"source":{"system":"sec-edgar","filing":"0001628280-23-034785","document":"wk-form4_1697825747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023034785/wk-form4_1697825747.xml","form_type":"4"}},{"id":1756936,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-20T18:15:56.000Z","date":"2023-10-19","kind":"other","planned":false,"acquired":false,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":38683,"source":{"system":"sec-edgar","filing":"0001628280-23-034785","document":"wk-form4_1697825747.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828023034785/wk-form4_1697825747.xml","form_type":"4"}},{"id":1870267,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T20:31:18.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 31, 2023, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":14500,"derivative":{"exercise_price":14.47,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-23-033775","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000120919123033775/doc4.xml","form_type":"4"}},{"id":1879794,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T18:41:34.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":12054,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12054,"derivative":{"exercise_price":25.74,"exercise_date":"2024-05-22","expiration_date":"2033-05-21","underlying":"Common Stock","underlying_shares":12054},"source":{"system":"sec-edgar","filing":"0001209191-23-031845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031845/doc4.xml","form_type":"4"}},{"id":1879793,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T18:41:34.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45088,"source":{"system":"sec-edgar","filing":"0001209191-23-031845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031845/doc4.xml","form_type":"4"}},{"id":2231613,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-15T20:47:59.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following June 13, 2022, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders,  subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":14500,"derivative":{"exercise_price":5.38,"expiration_date":"2032-06-12","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001209191-22-036981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000120919122036981/doc4.xml","form_type":"4"}},{"id":2234216,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T20:17:47.000Z","date":"2022-06-09","kind":"other","acquired":true,"shares":3374,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares transferred for no consideration to APNG 1 upon vesting of an RSU award held by the Reporting Person for the benefit of APNG 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":489485,"source":{"system":"sec-edgar","filing":"0001209191-22-036296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122036296/doc4.xml","form_type":"4"}},{"id":2234215,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T20:17:47.000Z","date":"2022-06-09","kind":"other","acquired":false,"shares":3374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."},{"field":"shares","element":"transactionShares","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration to APNG 1 in connection with the vesting of an RSU award. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":39061,"source":{"system":"sec-edgar","filing":"0001209191-22-036296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122036296/doc4.xml","form_type":"4"}},{"id":2256811,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T21:52:56.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":12810,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12810,"derivative":{"exercise_price":24.14,"exercise_date":"2023-05-23","expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":12810},"source":{"system":"sec-edgar","filing":"0001209191-22-031950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031950/doc4.xml","form_type":"4"}},{"id":2256810,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T21:52:56.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":42435,"source":{"system":"sec-edgar","filing":"0001209191-22-031950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031950/doc4.xml","form_type":"4"}},{"id":2566277,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-17T20:48:43.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":255160,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":662752},"source":{"system":"sec-edgar","filing":"0000899243-21-036431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036431/doc4.xml","form_type":"4"}},{"id":2566276,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-17T20:48:43.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1212122,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3148365},"source":{"system":"sec-edgar","filing":"0000899243-21-036431","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036431/doc4.xml","form_type":"4"}},{"id":2566275,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:48:43.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":156250,"price":16,"value":2500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":4080296,"source":{"system":"sec-edgar","filing":"0000899243-21-036431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036431/doc4.xml","form_type":"4"}},{"id":2566274,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:48:43.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3811117,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Alta Partners NextGen Fund II, L.P. (the \"APNG II\"). The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":3924046,"source":{"system":"sec-edgar","filing":"0000899243-21-036431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000089924321036431/doc4.xml","form_type":"4"}},{"id":2620066,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T00:52:36.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":2348,"price":37.5822,"value":88243.0056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.22 to $37.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":36030,"source":{"system":"sec-edgar","filing":"0001209191-21-049147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121049147/doc4.xml","form_type":"4"}},{"id":2620065,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T00:52:36.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":9322,"price":36.6316,"value":341479.7752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.19 to $37.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":38378,"source":{"system":"sec-edgar","filing":"0001209191-21-049147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121049147/doc4.xml","form_type":"4"}},{"id":2620064,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T00:52:36.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":1671,"price":43.53,"value":72738.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2021, the reporting person became entitled to receive 1,671 shares of the Issuer's common stock pursuant to an \"earn-out\" right in a letter agreement (the \"Letter Agreement\") entered into in connection with the Issuer's acquisition of all equity interests of TomegaVax, Inc. (\"TomegaVax\") on September 12, 2016 (the \"TomegaVax Merger\").  The Letter Agreement provides for certain payments to TomegaVax's former stockholders, for no additional consideration, prior to September 2024, in each case so long as the Issuer is continuing to pursue the development of the TomegaVax technology."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Letter Agreement, the Issuer will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Issuer's publicly traded common stock, or implied price per share of the Issuer's Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Issuer's clinical development at the time of the relevant event triggering the payment. The share price of the Issuer's publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Issuer's common stock for each trading day during a consecutive 90-day period."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Issuer or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Issuer or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the Letter Agreement can be made in cash or shares of the Issuer's common stock, at the discretion of the Issuer's board of directors.  On February 24, 2021, the Issuer achieved one of the milestones related to the specified per-share price of its common stock, which resulted in a $10.0 million payable to TomegaVax's former stockholders within 90 business days of achieving such milestone."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The number of shares issuable pursuant to the earn-out right was determined on July 1, 2021 (90 business days after the achievement of such milestone) based on the closing price of the Issuer's common stock on such date, as provided in the Letter Agreement.  On July 9, 2021, the Issuer completed the milestone payment to the former TomegaVax stockholders, including the reporting person, through a combination of cash payment and shares of common stock as determined by the Issuer's board of directors.  The reporting person's right to receive additional shares became fixed and irrevocable on September 12, 2016, the effective date of the TomegaVax Merger."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The remaining $20.0 million in milestone payments will be triggered if (i) the per-share price of the Issuer's publicly traded common stock is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Issuer's clinical development at the time of the relevant event triggering the payment or (ii) the per-share price of the Issuer's publicly traded common stock is at least $90 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).  The foregoing description of the terms of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which was filed as Exhibit 10.31 to the Issuer's Annual Report on Form 10-K for the year-ended December 31, 2020 filed with the Securities and Exchange Commission on February 25, 2021."}],"balance_after":47700,"source":{"system":"sec-edgar","filing":"0001209191-21-049147","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121049147/doc4.xml","form_type":"4"}},{"id":2630632,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T00:20:59.000Z","date":"2021-07-15","kind":"sale","acquired":false,"shares":11670,"price":35.5623,"value":415012.041,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.18 to $36.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":46029,"source":{"system":"sec-edgar","filing":"0001209191-21-047285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121047285/doc4.xml","form_type":"4"}},{"id":2641340,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T21:01:28.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":890,"price":46.2169,"value":41133.041,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.91 to $46.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":57699,"source":{"system":"sec-edgar","filing":"0001209191-21-045554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121045554/doc4.xml","form_type":"4"}},{"id":2641339,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T21:01:28.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":5986,"price":45.2275,"value":270731.815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $45.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":58589,"source":{"system":"sec-edgar","filing":"0001209191-21-045554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121045554/doc4.xml","form_type":"4"}},{"id":2641338,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T21:01:28.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":4794,"price":44.3065,"value":212405.361,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.81 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":64575,"source":{"system":"sec-edgar","filing":"0001209191-21-045554","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121045554/doc4.xml","form_type":"4"}},{"id":2661163,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T21:08:14.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":11670,"price":43.9452,"value":512840.484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $44.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":69369,"source":{"system":"sec-edgar","filing":"0001209191-21-042116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121042116/doc4.xml","form_type":"4"}},{"id":2679398,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T00:36:18.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":11670,"price":44.5615,"value":520032.705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":81039,"source":{"system":"sec-edgar","filing":"0001209191-21-038772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121038772/doc4.xml","form_type":"4"}},{"id":2697033,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-25T20:38:11.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":6748,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6748,"derivative":{"exercise_price":45.28,"exercise_date":"2022-05-21","expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":6748},"source":{"system":"sec-edgar","filing":"0001209191-21-035709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035709/doc4.xml","form_type":"4"}},{"id":2697032,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T20:38:11.000Z","date":"2021-05-21","kind":"grant","acquired":false,"shares":3374,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":92709,"source":{"system":"sec-edgar","filing":"0001209191-21-035709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035709/doc4.xml","form_type":"4"}},{"id":2699040,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T01:25:43.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":9095,"price":44.7667,"value":407153.1365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.22 to $45.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":89335,"source":{"system":"sec-edgar","filing":"0001209191-21-035596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035596/doc4.xml","form_type":"4"}},{"id":2699039,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T01:25:43.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":2575,"price":43.5721,"value":112198.1575,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.16 to $44.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 30,354 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) which was effected on April 5, 2021."}],"balance_after":98430,"source":{"system":"sec-edgar","filing":"0001209191-21-035596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035596/doc4.xml","form_type":"4"}},{"id":2805594,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":605,"price":121.65,"value":73598.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.60 - $122.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805593,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":1000,"price":120.83,"value":120830.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.53 - $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":605,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805592,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":1600,"price":119.7,"value":191520.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.29 - $120.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":1605,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805591,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":1300,"price":118.85,"value":154505.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.27 - $119.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":3205,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805590,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":1700,"price":117.62,"value":199954.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.27 - $118.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":4505,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805589,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":3871,"price":116.63,"value":451474.73,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.25 - $117.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":6205,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805588,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-05","kind":"sale","acquired":false,"shares":2600,"price":115.83,"value":301158.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.25 - $116.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":10076,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805587,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":100,"price":114.14,"value":11414.0,"ownership":{"direct":true},"balance_after":12676,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805586,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":5914,"price":113.03,"value":668459.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.54 - $113.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":12776,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805585,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":3280,"price":111.92,"value":367097.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.43 - $112.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":18690,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805584,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":1810,"price":110.63,"value":200240.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 - $111.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":21970,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805583,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":2796,"price":109.72,"value":306777.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.09 - $110.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":23780,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805582,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-04","kind":"sale","acquired":false,"shares":1100,"price":108.36,"value":119196.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.09 - $108.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":26576,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805581,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1878,"price":115.22,"value":216383.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.005 - $115.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":27676,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805580,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":400,"price":113.75,"value":45500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.38 - $114.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":29554,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805579,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":300,"price":112.59,"value":33777.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 - $112.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":29954,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805578,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1900,"price":111.62,"value":212078.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.265 - $112.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":30254,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":2805577,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2021-03-06T00:42:23.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":400,"price":110.89,"value":44356.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.24 - $111.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Shares held prior to the reported transaction consisted of 32,554 shares received in a pro rata distribution from APNG I subsequent to the Reporting Person's most recent Section 16 report, which distribution was not required to be reported pursuant to Section 16."}],"balance_after":32154,"source":{"system":"sec-edgar","filing":"0001209191-21-018405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919121018405/doc4.xml","form_type":"4"}},{"id":3008347,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-13T23:11:14.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":24355,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24355,"derivative":{"exercise_price":37.06,"exercise_date":"2021-05-21","expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":24355},"source":{"system":"sec-edgar","filing":"0001209191-20-054737","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120054737/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-26"}},{"id":3135255,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-26T21:00:29.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":28888,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28888,"derivative":{"exercise_price":37.06,"exercise_date":"2021-05-21","expiration_date":"2030-05-21","underlying":"Common Stock","underlying_shares":28888},"source":{"system":"sec-edgar","filing":"0001209191-20-032065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120032065/doc4.xml","form_type":"4"}},{"id":3140583,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2020-05-20T22:08:10.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":600,"price":72.74,"value":43644.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.72 - $72.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-031002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919120031002/doc4.xml","form_type":"4"}},{"id":3140582,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2020-05-20T22:08:10.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":4506,"price":72.25,"value":325558.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.68 - $72.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":600,"source":{"system":"sec-edgar","filing":"0001209191-20-031002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919120031002/doc4.xml","form_type":"4"}},{"id":3140581,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"member - potential 10% group"}}],"security":"Common Stock","published_at":"2020-05-20T22:08:10.000Z","date":"2020-05-18","kind":"sale","acquired":false,"shares":6432,"price":71.01,"value":456736.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.46 - $71.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":5106,"source":{"system":"sec-edgar","filing":"0001209191-20-031002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1207792/000120919120031002/doc4.xml","form_type":"4"}},{"id":3161364,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-05T21:55:23.000Z","date":"2020-05-01","kind":"sale","acquired":false,"shares":2700,"price":28.5972,"value":77212.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $28.675, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":71534,"source":{"system":"sec-edgar","filing":"0001209191-20-027256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120027256/doc4.xml","form_type":"4"}},{"id":3161363,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-05T21:55:23.000Z","date":"2020-05-01","kind":"sale","acquired":false,"shares":15758,"price":27.8995,"value":439640.321,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.51 to $28.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an estimated 29,170 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) initiated on April 29, 2020. The reporting person will file an amendment to this Form 4 if the final number of shares received by him in the distribution changes from the amount reported herein."}],"balance_after":74234,"source":{"system":"sec-edgar","filing":"0001209191-20-027256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120027256/doc4.xml","form_type":"4"}},{"id":3303106,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":6837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Guy P. Nohra in connection with the pro-rata distribution described in footnote (1) herein."}],"balance_after":6837,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303105,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11539,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Alta Bioequities, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Alta Bioequities, L.P. in connection with the pro-rata distribution described in footnote (5) herein.  Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. Daniel Janney is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein."}],"balance_after":11539,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303104,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Hudson Capital LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Hudson Capital, LLC, a limited liability company of which Peter A. Hudson is the managing member, in connection with the pro-rata distribution described in footnote (5) herein. Mr. Hudson disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":11538,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303103,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Represents the acquisition of the shares of Common Stock of the Issuer by Robert J. More in connection with the pro-rata distribution described in footnote (5) herein."}],"balance_after":11538,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303102,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":false,"shares":34615,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By APNG I Management"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by APNG I Management, without consideration, to its members."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303101,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":true,"shares":34615,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By APNG I Management"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. (\"APNG I\"), without consideration, to its general partner and limited partners."}],"balance_after":34615,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3303100,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":1,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":3,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":4,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":5,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":6,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":7,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":8,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":63327,"kind":"person","name":"JANNEY DANIEL","position":9,"cik":"0001198325","reported_name":"JANNEY DANIEL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-24T18:24:58.000Z","date":"2020-01-22","kind":"other","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Alta Partners NextGen Fund I L.P. (\"APNG I\"), without consideration, to its general partner and limited partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of 2,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta Partners VIII, L.P. (\"Alta VIII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their respective pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their respective pecuniary interests therein."}],"balance_after":10519200,"source":{"system":"sec-edgar","filing":"0001209191-20-004922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919120004922/doc4.xml","form_type":"4"}},{"id":3391042,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-10-18T23:52:04.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":277777,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":277777},"source":{"system":"sec-edgar","filing":"0001209191-19-053662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919119053662/doc4.xml","form_type":"4"}},{"id":3391041,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2019-10-18T23:52:04.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":60822,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":60822},"source":{"system":"sec-edgar","filing":"0001209191-19-053662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919119053662/doc4.xml","form_type":"4"}},{"id":3391040,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2019-10-18T23:52:04.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":1666666,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1666666},"source":{"system":"sec-edgar","filing":"0001209191-19-053662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919119053662/doc4.xml","form_type":"4"}},{"id":3391039,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-18T23:52:04.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":60822,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."}],"balance_after":60822,"source":{"system":"sec-edgar","filing":"0001209191-19-053662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919119053662/doc4.xml","form_type":"4"}},{"id":3391038,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-18T23:52:04.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":1944443,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Alta Partners NextGen Fund I, L.P. (APNG 1). The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":1944443,"source":{"system":"sec-edgar","filing":"0001209191-19-053662","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919119053662/doc4.xml","form_type":"4"}},{"id":3504736,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2019-06-03T19:38:03.000Z","date":"2019-05-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.22,"expiration_date":"2029-05-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-19-003242","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019003242/primarydocument.xml","form_type":"4"}},{"id":3632257,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-26T17:16:15.000Z","date":"2019-02-22","kind":"purchase","acquired":true,"shares":100000,"price":2.5,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's public offering at the offering price of $2.50 per share."}],"balance_after":255942,"source":{"system":"sec-edgar","filing":"0001562180-19-001424","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218019001424/primarydocument.xml","form_type":"4"}},{"id":3862976,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":3,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":4,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":5,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":6,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":7,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":8,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-07-23T17:01:38.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":1239007,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"APNG I owns 504,547 shares of Series B Preferred Stock. Alta VIII owns 734,460 shares of Series B Preferred Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1239007},"source":{"system":"sec-edgar","filing":"0001209191-18-043627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919118043627/doc4.xml","form_type":"4"}},{"id":3862975,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":3,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":4,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":5,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":6,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":7,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":8,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-07-23T17:01:38.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":10030193,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"APNG I owns 2,941,718 shares of Series A Preferred Stock. Alta VIII owns 7,088,475 shares of Series A Preferred Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10030193},"source":{"system":"sec-edgar","filing":"0001209191-18-043627","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919118043627/doc4.xml","form_type":"4"}},{"id":3862974,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":3,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":4,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":5,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":6,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":7,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":8,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T17:01:38.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":250000,"price":18,"value":4500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Consists of 3,557,377 shares held of record by APNG I and 7,961,823 shares held of record by Alta VIII."}],"balance_after":11519200,"source":{"system":"sec-edgar","filing":"0001209191-18-043627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919118043627/doc4.xml","form_type":"4"}},{"id":3862973,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":110408,"kind":"organization","name":"Alta Partners VIII, L.P.","position":1,"cik":"0001399763","reported_name":"Alta Partners VIII, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":110407,"kind":"organization","name":"Alta Partners Management VIII, LLC","position":2,"cik":"0001399894","reported_name":"Alta Partners Management VIII, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144083,"kind":"organization","name":"Alta Partners NextGen Fund I Management, LLC","position":3,"cik":"0001736001","reported_name":"Alta Partners NextGen Fund I Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144084,"kind":"organization","name":"Alta Partners NextGen Fund I, L.P.","position":4,"cik":"0001698110","reported_name":"Alta Partners NextGen Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143450,"kind":"person","name":"CHAMPSI FARAH","position":5,"cik":"0001198321","reported_name":"CHAMPSI FARAH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135397,"kind":"person","name":"Hudson Peter A","position":6,"cik":"0001674884","reported_name":"Hudson Peter A","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24127,"kind":"person","name":"MORE ROBERT J","position":7,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39204,"kind":"person","name":"NOHRA GUY P","position":8,"cik":"0001198330","reported_name":"NOHRA GUY P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T17:01:38.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":11269200,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 3,446,265 shares held of record by Alta Partners NextGen Fund I, L.P. (\"APNG I\") and 7,822,935 shares held of record by Alta Partners VIII, L.P. (\"Alta VIII\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares directly held by Alta VIII are indirectly held by Alta Partners Management VIII, LLC (\"Alta Management VIII\"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares directly held by APNG I are indirectly held by Alta Partners NextGen Fund I Management, LLC (\"APNG I Management\"), which is the general partner of APNG I. The individual managing directors of APNG I Management are Robert More, Peter Hudson and Daniel Janney. The managing directors of APNG I Management exercise sole voting and investment control with respect to the shares held by APNG I. The individual managing directors of APNG I Management disclaim beneficial ownership of all shares held by APNG I, except to the extent of their pecuniary interests therein."}],"balance_after":11269200,"source":{"system":"sec-edgar","filing":"0001209191-18-043627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1736001/000120919118043627/doc4.xml","form_type":"4"}},{"id":3908503,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2018-06-04T21:43:22.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":15.08,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-002850","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000156218018002850/primarydocument.xml","form_type":"4"}},{"id":3979725,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-29T20:50:47.000Z","date":"2018-03-29","kind":"sale","acquired":false,"shares":14429,"price":18.78,"value":270976.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $18.75 to $18.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":178820,"source":{"system":"sec-edgar","filing":"0001140361-18-016002","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036118016002/doc1.xml","form_type":"4"}},{"id":3979724,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-29T20:50:47.000Z","date":"2018-03-28","kind":"sale","acquired":false,"shares":10000,"price":18.84,"value":188400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $18.8213 to $18.869, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":193249,"source":{"system":"sec-edgar","filing":"0001140361-18-016002","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036118016002/doc1.xml","form_type":"4"}},{"id":4247387,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2017-08-01T16:24:51.000Z","date":"2017-08-01","kind":"exercise","acquired":false,"shares":32892,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32892},"source":{"system":"sec-edgar","filing":"0001140361-17-029597","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036117029597/doc1.xml","form_type":"4"}},{"id":4247386,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2017-08-01T16:24:51.000Z","date":"2017-08-01","kind":"exercise","acquired":false,"shares":136286,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":136286},"source":{"system":"sec-edgar","filing":"0001140361-17-029597","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036117029597/doc1.xml","form_type":"4"}},{"id":4247385,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-01T16:24:51.000Z","date":"2017-08-01","kind":"exercise","acquired":true,"shares":32892,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."}],"balance_after":203249,"source":{"system":"sec-edgar","filing":"0001140361-17-029597","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036117029597/doc1.xml","form_type":"4"}},{"id":4247384,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-01T16:24:51.000Z","date":"2017-08-01","kind":"exercise","acquired":true,"shares":136286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."}],"balance_after":170357,"source":{"system":"sec-edgar","filing":"0001140361-17-029597","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656328/000114036117029597/doc1.xml","form_type":"4"}}]}